Yanqiu Zhao

机构：Harbin Medical University, First Affiliated Hospital of Harbin Medical University · ORCID：0009-0009-8085-2302

发表论文 32 篇 · 总被引 361 次 · h-index 11

代表论文

• A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial (2025 · Nature Medicine · 被引 88)
• Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial (2024 · The Lancet Respiratory Medicine · 被引 42)
• Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study (2024 · Journal of Clinical Oncology · 被引 36)
• Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial (2025 · The Lancet · 被引 33)
• Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial (2025 · Nature Medicine · 被引 30)
• First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial (2025 · 癌症：英文版 · 被引 21)